"Anti-Obesity Agents" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Agents that increase energy expenditure and weight loss by neural and chemical regulation. Beta-adrenergic agents and serotoninergic drugs have been experimentally used in patients with non-insulin dependent diabetes mellitus (NIDDM) to treat obesity.
Descriptor ID |
D019440
|
MeSH Number(s) |
D27.505.954.427.140
|
Concept/Terms |
Anti-Obesity Agents- Anti-Obesity Agents
- Agents, Anti-Obesity
- Anti Obesity Agents
- Anti-Obesity Drugs
- Anti Obesity Drugs
- Drugs, Anti-Obesity
- Antiobesity Drugs
- Drugs, Antiobesity
- Antiobesity Agents
- Agents, Antiobesity
Weight-Loss Agents- Weight-Loss Agents
- Agents, Weight-Loss
- Weight Loss Agents
- Weight-Loss Drugs
- Drugs, Weight-Loss
- Weight Loss Drugs
|
Below are MeSH descriptors whose meaning is more general than "Anti-Obesity Agents".
Below are MeSH descriptors whose meaning is more specific than "Anti-Obesity Agents".
This graph shows the total number of publications written about "Anti-Obesity Agents" by people in this website by year, and whether "Anti-Obesity Agents" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
2000 | 1 | 0 | 1 |
2003 | 1 | 0 | 1 |
2004 | 0 | 1 | 1 |
2005 | 2 | 0 | 2 |
2007 | 0 | 1 | 1 |
2009 | 0 | 1 | 1 |
2010 | 0 | 1 | 1 |
2011 | 1 | 0 | 1 |
2015 | 0 | 1 | 1 |
2016 | 1 | 0 | 1 |
2019 | 1 | 0 | 1 |
2022 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Anti-Obesity Agents" by people in Profiles.
-
Kyrillos J. Semaglutide 2.4-mg injection as a novel approach for chronic weight management. Am J Manag Care. 2022 12; 28(15 Suppl):S297-S306.
-
Ritchey ME, Harding A, Hunter S, Peterson C, Sager PT, Kowey PR, Nguyen L, Thomas S, Cainzos-Achirica M, Rothman KJ, Andrews EB, Anthony MS. Cardiovascular Safety During and After Use of Phentermine and Topiramate. J Clin Endocrinol Metab. 2019 02 01; 104(2):513-522.
-
Lunsford KE, Bodzin AS, Reino DC, Wang HL, Busuttil RW. Dangerous dietary supplements: Garcinia cambogia-associated hepatic failure requiring transplantation. World J Gastroenterol. 2016 Dec 07; 22(45):10071-10076.
-
Dietz WH, Baur LA, Hall K, Puhl RM, Taveras EM, Uauy R, Kopelman P. Management of obesity: improvement of health-care training and systems for prevention and care. Lancet. 2015 Jun 20; 385(9986):2521-33.
-
Kim GW, Lin JE, Valentino MA, Colon-Gonzalez F, Waldman SA. Regulation of appetite to treat obesity. Expert Rev Clin Pharmacol. 2011 Mar; 4(2):243-59.
-
Valentino MA, Terzic A, Waldman SA. Sizing up pharmacotherapy for obesity. Clin Transl Sci. 2010 Jun; 3(3):123-5.
-
Brawer R, Brisbon N, Plumb J. Obesity and cancer. Prim Care. 2009 Sep; 36(3):509-31.
-
Kopelman PG. Medical management of obesity. Br J Hosp Med (Lond). 2007 Feb; 68(2):89-93.
-
Snow V, Barry P, Fitterman N, Qaseem A, Weiss K. Pharmacologic and surgical management of obesity in primary care: a clinical practice guideline from the American College of Physicians. Ann Intern Med. 2005 Apr 05; 142(7):525-31.
-
Kopelman PG. Clinical treatment of obesity: are drugs and surgery the answer? Proc Nutr Soc. 2005 Feb; 64(1):65-71.